Severe Non-Renal SLE Not Controlled by Cyclophosphamide-Based First-Line Therapy

This protocol addresses patients with severe systemic lupus erythematosus involving major non-renal organs whose disease has not been brought under control by first-line treatment.

Clinical Scenario

Severe SLE without renal involvement, presenting with major organ-threatening disease — cerebritis, myelitis, pneumonitis, mesenteric vasculitis — or thrombocytopenia with platelets <20 × 10⁹/L, TTP-like disease, acute haemophagocytic syndrome, rash extending beyond 18% body surface area, SLEDAI >12, or at least one BILAG A manifestation.

When First-Line Treatment Did Not Achieve Remission

Prior therapy — targets not reached

A first-line regimen including hydroxychloroquine, intravenous methylprednisolone, oral prednisone, intravenous cyclophosphamide, and/or belimumab or anifrolumab did not achieve the treatment targets: SLEDAI score of 0 (remission) or SLEDAI ≤4 (low disease activity state). This protocol defines the next clinical step after that failure.

Next-Line Treatment Approach

The escalation protocol for this refractory scenario involves rituximab. Complete dosing, sequencing, monitoring requirements, and the full decision algorithm are available in the structured protocol.

Treatment Goals

The primary aim is SLEDAI score of 0 (remission); where full remission is not attainable, SLEDAI ≤4 (low disease activity state) is the minimum acceptable target.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/ard-2023-224762

Severe disease: major organ threatening disease (cerebritis, myelitis, pneumonitis, mesenteric vasculitis); thrombocytopenia with platelets <20 × 10⁹/L; TTP-like disease or acute haemophagocytic syndrome; rash >18% BSA SLEDAI >12; ≥1 BILAG A manifestations.

In patients with organ-threatening or life-threatening disease, intravenous cyclophosphamide (2b/C) should be considered; in refractory cases, rituximab (2b/C) may be considered.

Early SLE diagnosis (including serological assessment), regular screening for organ involvement (especially nephritis), prompt initiation of treatment aiming at remission (or low disease activity if this is not possible) and strict adherence to treatment are essential to prevent flares and organ damage, improve prognosis and enhance quality of life.

View source ↗